A Phase 1 Study of BPI-15086 in Patients With Epidermal Growth Factor Receptor T790M Mutation-positive Non-Small Cell Lung Cancer Who Have Progressed on Previous EGFR Tyrosine Kinase Inhibitor Therapy
Latest Information Update: 05 Nov 2021
At a glance
- Drugs BPI 15086 (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors Betta Pharmaceuticals Co Ltd
- 15 Jul 2019 Status changed from recruiting to completed.
- 14 Apr 2017 Status changed from not yet recruiting to recruiting.
- 06 Oct 2016 New trial record